E
Eric Yvon
Researcher at George Washington University
Publications - 70
Citations - 7609
Eric Yvon is an academic researcher from George Washington University. The author has contributed to research in topics: Immune system & Cytotoxic T cell. The author has an hindex of 30, co-authored 68 publications receiving 6892 citations. Previous affiliations of Eric Yvon include University of Texas MD Anderson Cancer Center & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
Marina Cavazzana-Calvo,Hacein-Bey S,Geneviève de Saint Basile,Fabian Gross,Eric Yvon,Patrick Nusbaum,Françoise Selz,Christophe Hue,Stéphanie Certain,Jean-Laurent Casanova,Philippe Bousso,Françoise Le Deist,Alain Fischer +12 more
TL;DR: A gene therapy trial for SCID-X1 was initiated, based on the use of complementary DNA containing a defective gammac Moloney retrovirus-derived vector and ex vivo infection of CD34+ cells, which provided full correction of disease phenotype and clinical benefit.
Journal ArticleDOI
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin Pule,Barbara Savoldo,G. Doug Myers,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Heidi V. Russell,Gianpietro Dotti,Gianpietro Dotti,M. Helen Huls,Enli Liu,Adrian P. Gee,Adrian P. Gee,Zhuyong Mei,Eric Yvon,Heidi L. Weiss,Hao Liu,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +22 more
TL;DR: It is shown in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity.
Journal ArticleDOI
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde,Amanda Corder,Kevin Chow,Malini Mukherjee,Aidin Ashoori,Yvonne Kew,Yi Jonathan Zhang,David S. Baskin,Fatima A. Merchant,Vita S. Brawley,Tiara T. Byrd,Simone Krebs,Meng Fen Wu,Hao Liu,Helen E. Heslop,Stephen Gottachalk,Eric Yvon,Nabil Ahmed +17 more
TL;DR: Both HER2/IL-13Rα2-bispecific T cell products offset antigen escape, producing enhanced effector activity in vitro immunoassays and in an orthotopic xenogeneic murine model.
Journal ArticleDOI
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
Tessa Gargett,Wenbo Yu,Gianpietro Dotti,Eric Yvon,Susan N Christo,John D. Hayball,John D. Hayball,Ian D. Lewis,Malcolm K. Brenner,Michael P. Brown,Michael P. Brown,Michael P. Brown +11 more
TL;DR: The events following activation of third-generation CAR T cells specific for GD2 suggest that deletion also occurs in vivo and that PD-1-targeted combination therapy approaches may be useful to augment CAR T-cell efficacy and persistence in patients.
Journal ArticleDOI
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation
Persis Amrolia,Giada Muccioli-Casadei,Helen Huls,Stuart Adams,April G. Durett,Adrian P. Gee,Eric Yvon,Heidi L. Weiss,Mark Cobbold,H. Bobby Gaspar,Cliona M. Rooney,Ingrid Kuehnle,Victor Ghetie,John Schindler,Robert A. Krance,Helen E. Heslop,Paul Veys,Ellen S. Vitetta,Malcolm K. Brenner +18 more
TL;DR: It is demonstrated that allodepleted donor T cells can be safely used to improve T-cell recovery after haploidentical SCT and may broaden the applicability of this approach.